LINC02129: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

Target Name: LINC02129

NCBI ID: G105371156

LINC02129

Other Name(s): Long intergenic non-protein coding RNA 2129 | long intergenic non-protein coding RNA 2129

LINC02129: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

LINC02129 is a long intergenic non-protein coding RNA (lncRNA) that has been identified in various studies as a potential drug target or biomarker. It is a non-coding RNA molecule that is expressed in a variety of tissues and cells, including brain, heart, and pancreas, and is involved in the regulation of various cellular processes. In this article, we will explore the potential role of LINC02129 as a drug target or biomarker.

Drug Target Potential

LINC02129 has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. It is a long non-coding RNA molecule that has a length of approximately 290 nucleotides. It is expressed in various tissues and cells and is involved in the regulation of various cellular processes, including cell adhesion, migration, and transcriptional regulation.

One of the key features of LINC02129 is its ability to interact with various protein molecules. It has been shown to interact with several proteins, including the protein encoded by the SNP gene (SNP1) and the protein encoded by the HSP70 gene (HSP70). These interactions may be important for LINC02129's function in regulating cellular processes.

In addition to its interaction with proteins, LINC02129 has also been shown to play a role in the regulation of gene expression. It has been shown to interact with the RNA polymerase II (RNA-II) complex, which is responsible for transcribing DNA into RNA. This interaction may be important for LINC02129's function in regulating gene expression.

Biomarker Potential

LINC02129 has also been identified as a potential biomarker due to its unique expression patterns and its involvement in various cellular processes. It is expressed in various tissues and cells, including brain, heart, and pancreas, and is detectable using various techniques, such as qRT-PCR and western blotting.

One of the potential applications of LINC02129 as a biomarker is its ability to be downregulated in various diseases, such as cancer. It has been shown to be downregulated in various cancer types, including breast, ovarian, and colorectal cancers. This downregulation may be important for the development and progression of these diseases.

Another potential application of LINC02129 as a biomarker is its ability to be increased in response to certain treatments. For example, it has been shown to be increased in the hearts of dogs that have been treated with dobutamine, a drug that is used to treat heart failure. This increase in LINC02129 may be important for the efficacy of dobutamine.

Conclusion

In conclusion, LINC02129 is a long intergenic non-protein coding RNA that has been identified as a potential drug target or biomarker. Its unique structure and its involvement in various cellular processes make it an attractive candidate for further research. Further studies are needed to determine the exact role of LINC02129 in cellular processes and its potential as a drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2129

The "LINC02129 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02129 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets